Solubilization of poorly water-soluble drugs using solid dispersions

Recent Patents on Drug Delivery and Formulation

Volumn 7, Issue 2, 2013, Pages 122-133

  Tran, Thao T D ^a   Tran, Phuong H L ^a   Khanh, Tran N ^a   Van, Toi V ^a   Lee, Beom Jin ^b  

^a INTERNATIONAL UNIVERSITY   (Viet Nam)

^b Ajou University   (South Korea)

Author keywords

Characterization method; Poorly water soluble drugs; Preparation method; Solid dispersion; Solubilization

Indexed keywords

CANDESARTAN HEXETIL; CARBAMAZEPINE; CYCLODEXTRIN; DANAZOL; EBASTINE; FENOFIBRATE; GRISEOFULVIN; ITRACONAZOLE; POLOXAMER; ROTIGOTINE; SILYMARIN; TACROLIMUS;

CHEMICAL PROCEDURES; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SOLUBILITY; ELECTROSPINNING; FUSION METHOD; INFRARED SPECTROSCOPY; INTERMETHOD COMPARISON; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARTICLE SIZE; PHASE SEPARATION; PRIORITY JOURNAL; REVIEW; SOLID DISPERSION; SOLVENT EVAPORATION; SPRAY DRYING; SUPERCRITICAL FLUID; TEMPERATURE SENSITIVITY; WETTABILITY; X RAY DIFFRACTION;

BIOLOGICAL AVAILABILITY; DRUG CARRIERS; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; DRUG STABILITY; HUMANS; PATENTS AS TOPIC; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84880161925     PISSN: 18722113     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872211311307020004     Document Type: Review

References (90)

1. Seo, M.-H., Choi, I.-J. Polymeric composition for solubilizing poorly water soluble drugs and process for the preparation thereof. US6616941 (2003).
2. Chornet, E., Ishizawa, C., Dumitriu, S. Drug delivery system for poorly water soluble drugs. US20030157171 (2003).
3. United States Pharmacopoeia (USP30/NF 25).
4. Samejima, M., Noda, K., Kobayashi, M., Osawa, T. Process for micronizing slightly-soluble drug. US5202129 (1993).
5. Deeb, V.M., Rouse, M.W. Particle size reduction using supercritical materials. US6680110 (2004).
6. Magdassi, S., Sela, Y., Karen, C. Formulations For Poorly Soluble Drugs. US20080038333 (2008).
7. Birudaraj, K., Prince, A., McCarthy, K. Polymorphic antiviral nucleoside compounds. US20050130915 (2005).
8. Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 2000; 50: 47-60.
9. Koretke, T.W., Bhatt, K.H. Novel solid dispersion compositions. US20030212102 (2003).
10. Babcock, W.C., Friesen, D.T., Nightingale, J.A.S., Shanker, R.M. Pharmaceutical solid dispersions. US20040013734 (2004).
11. Fort, J.J., Krill, S.L., Law, D., Qiu, Y., Schmitt, E.A. Inhibitors of crystallization in a solid dispersion. US20070249692 (2007).
12. Holm, P., Norling, T. Solid dispersions comprising tacrolimus. US20100008984 (2010).
13. Cahill, J., Bateman, F. Solid pharmaceutical composition comprising 4-cyano-trifluoro-3(4-fluorophenyl-sulphonyl)-2hydroxymethylpropiono-m toluidide and pvp. US20040138299 (2004).
14. Wolff, HM., Arth, C., Quere, L., Müller, W. Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine. WO2011076879 (2011).
15. Farshi, F., Koc, F., Soylemez, S., Durmus, S. Producing stable Adefovir Dipivoxil solid dispersions in amorphous state. EP 2343056A1 (2011).
16. Rao, K.R., Bhanumathi, N., Yadav, J.S., Krishnaveni, N.S. Inclusion complex of rifampicin, an anti-tubercular drug, with cyclodextrin or 2-hydroxypropyl-cyclodextrin and a process there of. US7001893 (2006).
17. Badwan, A., Abumalooh, A., Haddadin, M., Ibrahim, H. Method for solubilizing drugs using cyclodextrins and carboxylic acids. US5646131 (1997).
18. Loftsson, T., Brewster M.E. Pharmaceutical Applications of Cyclodextrins. 1. Drug Solubilization and Stabilization. J. Pharm. Sci. 1996; 85: 1027-1025.
19. Valcavi, U., Monterosso, V., Caponi, R., Bosone, E., Wachter, W., Szejtli, J. Inclusion complexes with silybinin, their preparation and pharmaceutical compositions containing them. US5198430 (1993).
20. Woo, J.S., Yi, H.G., Park, J.H. Amorphous Taclolimus Solid Dispersion Having an Enhanced Solubility and Pharmaceutical Composition Comprising Same. US20080153866 (2008).
21. Breitenbach, J., Alani, L., Berndl, G.S., Liepold, B., Reinhold, U. Solid pharmaceutical dosage form. US20050048112 (2005).
22. Woo, J.S., Chang, H.C. Non-crystalline cefuroxime axetil solid dispersant, process for preparing same and composition for oral administration thereof. US6107290 (2000).
23. Kelm, G.R., Dobrozsi, D.J. Solid dispersion compositions of tebufelone. US5281420 (1994).
24. Shin, H.J., Lim, J.L., Ki, M.H., Yun, J.H. Solid dispersion of tacrolimus. US20060177500 (2006).
25. Smithey, D.T, Friesen, D.T., Miller, W.K., Babcock, W.C. Solid compositions of low-solubility drugs and poloxamers. US20070141143 (2007).
26. Roma, M.J., Mestre, C.J., Suñé, N.J.M. Solid oral forms of ebastine. US20090304791 (2009).
27. Patel, K.H. Pillai, R.S. Solid dispersion compositions. US7423004 (2008).
28. Greil, J., Wolf, S., Ludescher, J. Novel Co-Precipitate of Amorphous Rosiglitazone. US20070225337 (2007).
29. Abrahamsson, B., Odman, J. Pharmaceutical Compositions. US20080058399 (2008).
30. Kulkarni, S., Dalal, S.K., Jahagirdar, H.A. Solid dispersion of rifaximin. US20120214833 (2012).
31. Crison, J.R., Amidon, G.L. Method and formulation for increasing the bioavailability of poorly water-soluble drugs. US5993858 (1999).
32. Andrew, X.C., Cheni, K., Christopher, A. Oral formulations for picoplatin. WO2009011861 (2009).
33. Bock, T., Friedl, T., Hantke, T., Neumann, J. Rosenberg, J. Solid Pharmaceutical Form Comprising and Ltb4 Antagonist. US20070237823 (2007).
34. Chatterji, A., Dong, Z., Sandhu, H.K., Shah, N.H. Pharmaceutical compositions for poorly soluble drugs. US20080293787 (2008).
35. Emås M, Nyqvist, H. Methods of studying aging and stabilization of spray-congealed solid dispersions with carnauba wax. 1. Microcalorimetric investigation, Int J Pharm 2000; 197: 117-27.
36. Passerini, N., Qi, S., Albertini, B., Grassi, M., Rodriguez, L., Craig, D.Q.M. Solid lipid microparticles produced by spray congealing: Influence of the atomizer on microparticle characteristics and mathematical modeling of the drug release. J Pharmaceut Sci 2010, 99: 916-31.
37. Albertini, B., Mezzena, M., Passerini, N., Rodriguez, L., Scalia, S. Evaluation of spray congealing as technique for the preparation of highly loaded solid lipid microparticles containing the sunscreen agent, avobenzone. J Pharmaceut Sci 2009; 98: 2759-69.
38. Fini A, Rodriguez L, Cavallari C, Albertini B, Passerini N. Ultrasound-compacted and spray-congealed indomethacin/polyethyleneglycol systems. Int J Pharm 2002, 247: 11-22.
39. Passerini, N., Albertini, B., Perissutti, B., Rodriguez, L. Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. Int J Pharm 2006; 318: 92-102.
40. Hoshino, T., Kusaki, F., Fukui, I. Solid dispersion preparation. US20070248681 (2007).
41. Brodin, A., Frank, S., Ye, C. Method of preparing solid dispersions. US20030104065 (2003).
42. Kumar, V. Solid dispersions of opioid antagonists. US20070082053 (2007).
43. Krape, P.J., Chang, S.C., Hein, W.A., Teleha, C.A. Process for manufacturing paroxetine solid dispersions. US5955475 (1999).
44. Ronsen, B., Sadhale, Y.D., El-Rashidy, R. Amorphous paroxetine composition US6503927 (2003).
45. Riegelman, S., Chiou, W.L. Increasing the absorption rate of insoluble drugs. US4151273 (1979).
46. Beyerinck, R.A., Diebele, H.L.M., Dobry, D.E., Ray, R.J., Settell, D.M., Spence, K.R. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus. US20040194338 (2004).
47. Zijlstra, G.S., Dickhoff, B.H.J., Van Drooge, D.J. Hinrichs, W.L.J., Frijlink, H.W. Process for preparing formulations of lypophilic active substances by spray freezing drying. US20070098864 (2007).
48. Stefan, R., Meergans, D. Aliskiren in form of a solid dispersion. EP2011001990 (2011).
49. Kaushik, P., Thaimattam, R., Prasad, M. Febuxostat solid dispersion. WO2012140632 (2012).
50. Woo, J.S., Kim, H.J., Kim, Y.H. Method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby. US20060078619 (2006).
51. Johnston, K.P., Williams, R.O., Young, T.J., Chen, X. Preparation of drug particles using evaporation precipitation into aqueous solutions. US20020081334 (2002).
52. Miller, D.A., Mcconville, J.T., Mcginity, J.W., Williams, R.O. Stabilized Hme Composition With Small Drug Particles. US20080274194 (2008).
53. Ignatious, F., Baldoni, J.M. Electrospun pharmaceutical compositions. US20030017208 (2003).
54. Ignatious, F., Sun, L. Electrospun amorphous pharmaceutical compositions. US20060013869 (2006).
55. Zhang, X., Wu, D., Lai, J., Lu, Y., Yin, Z., Wu, W. Piroxicam/2hydroxypropyl-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique. J Pharmaceut Sci, 2009, 98: 665-675.
56. Sun, N., Wei, X., Wu, B., Chen, J., Lu, Y., Wu, W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powder Tech, 2008, 82: 72-80.
57. Lu, Y., Zhang, X., Lai, J., Yin, Z., Wu, W. Physical characterization of meloxicam-cyclodextrin inclusion complex pellets prepared by a fluid-bed coating method. Particuology 2009; 7: 1-8.
58. Tang, N., Lai, J., Chen, Y-P., Lu, Y., Wu, W. Fenofibrate solid dispersion pellets prepared by fluid-bed coating: physical characterization, improved dissolution and oral bioavailability in beagle dogs. J Chin Pharmaceut Sci 2009; 18: 156-61.
59. Sun, N., Zhang, X., Lu, Y., Wu, W. In vitro evaluation and pharmacokinetics in dogs of solid dispersion pellets containing Silybum marianum extract prepared by fluid-bed coating. Planta Med 2008; 74: 126-132.
60. Kessler, T., Breitenbach, J., Schmidt, C., Degenhardt, M., Rosenberg, J., Krull, H. Process for producing a solid dispersion of an active ingredient. US20090311414 (2009).
61. Diederich, A., Timpe, C., Ries, A., Ottinger, I., Mueller, I., Herbig, M., Schuetz, H., Lakshman, J.P., Kalb, O. Solid dispersion of a neurokinin antagonist. US20100015225 (2010).
62. Berndl, G., Degenhardt, M., Mäegerlein, M., Dispersyn, G. Itraconazole compositions with improved bioavailability. US20090214656 (2009).
63. Olsen, S., Doney, J.A., Shores, C.S. Benzoquinones of enhanced bioavailability. US20070026072 (2007).
64. Brough, C., Mcginity, J.W., Miller Dave A., Dinunzio, J.C., Williams, R.O. Thermo-kinetic mixing for pharmaceutical applications. US20090053315 (2009).
65. Fawzi, M.B., Ali, K.A., Shah, S.M. Bazedoxifene ascorbate. US7504394 (2009).
66. Ghogh, I., Snyder, J., Tong, W.Q., Vippagunta, S. Method of making solid dispersions of highly crystalline therapeutic compounds. US20100038816 (2010).
67. Jacobs, I.C., Higgins, J.D., Guillot, M., Franson, N.M., Rocco, W.L., Abu-izza, K.A. Aamorphous solid dispersions. US20080160080 (2008).
68. Leuner, C, Dressman, J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000; 50:47-60.
69. Ronsen, B., Sadhale, Y.D., El-rashidy, R. Amorphous paroxetine composition. US6503927 (2003).
70. Trewartha, G., Navarro, E.F., Rees, D.C., Vinkovic, M., Woodhead, A., Wyatt, P.G. 4-(2, 6-Dichloro-benzoylamino)-1Hpyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) amide for the Treatment of Cancer. US20090318500 (2009).
71. Dong, L.C., Han, J.E., Pollock-dove, C., Wong, P.S.L. Oral delivery system comprising a drug/polymer complex. US20050287212 (2005).
72. Kumar, V. Solid dispersion of opioid antagonists. US7914776 (2011).
73. Krape, P., Chang, S., Hein II W., Teleha, C. Novel process for manufacturing paroxetine solid dispersions. EP19980931648 (2005).
74. Schroeder, R., Heitermann, T. Solid dispersion product containing n-aryl urea-based compound. US20090143423 (2009).
75. Maxfield, M., Christiani, R., Murthy, S. N., Tuller, H. US5385776 (1995).
76. Chen, A.X., Fan, J., Yamaguchi, M. Solid dispersion of alphaketoamide derivatives. US20120016020 (2012).
77. Yeom II D., Wang, H.S., Park, J.S., Song, W.H. Solid dispersion comprising tacrolimus and entericcoated macromolecule. US20080132533 (2008).
78. Verhoeven, E., Voorspoels, J., Gonnissen, Y., Ruysschaert, Y. Solid dispersion comprising an anti-HIV agent. WO2011029909 (2011).
79. Birtalan, E., Hoelig, P., Lindley, DJ., Sanzgiri, Y.D., Tong, P. Melt-extruded solid dispersions containing an apoptosis-inducing agent. US20120108590 (2012).
80. Catron, N., Lindley, D., Miller, JM., Schmitt, EA., Tong, P. Solid dispersions containing an apoptosis-inducing agent. US20120277210 (2012).
81. Stahl P.H, Wermuth C.G (Eds.). Handbook of Pharmaceutical Salts: Properties, Selection and Use. Weinheim, Wiley-VCH. 2002.
82. Kramer, A., Ries, A., Siepe, S., Lückel, B. Pharmaceutical compositions comprising a ph-dependent drug, a pH modifier and a retarding agent. US20090214645 (2009).
83. Siepe S, Lueckel B, Kramer A, Ries A, Gurny R. Strategies for the design of hydrophilic matrix tablets with controlled microenvironmental pH. Int J Pharm 2006; 316: 14-20.
84. Tran PHL, Tran HTT, Lee B-J. Modulation of microenvironmental pH and crystallinity of ionizable telmisartan using alkalizers in solid dispersions for controlled release. J Control Release 2008; 129: 59-65.
85. Tran TTD, Tran PHL, Lee B-J. Dissolution-modulating mechanism of alkalizers and polymers in a nanoemulsifying solid dispersion containing ionizable and poorly water-soluble drug. Eur J Pharm Biopharm 2009; 72: 83-90.
86. Tran TTD, Tran PHL, Choi HG, Han HK, Lee B-J. The roles of acidifiers in solid dispersions and physical mixtures. Int J Pharm 2010; 384: 60-66.
87. Dyar, S.C., Lodaya, M.P., Mollan, J., Matthew, J., Shah, U., Sun, H.J., Teweldemedhin, Z. Pharmaceutical compositions of amorphous atorvastatin and process for preparing same. US20090088465 (2009).
88. Janssens, S., Van Den, M.G. Enhancing solubility and dissolution rate of poorly soluble drugs. US20090311325 (2009).
89. Nakano, T., Tanaka, T., Izumi, S. Process for producing medicinal solid dispersion. US20040013736 (2004).
90. Lee, S.D. Solid dispersion system of pranlukast with improved dissolution and method for preparing the same. US20030077322 (2003).